Eli nqaku liza kukunceda ukhethe ukuba yeyiphi ofanelekela ngakumbi ngokuphendula le mibuzo ilandelayo:
1.Nguwuphi umahluko phakathi kwe-tirzepatide kunye ne-retatrutide?
2.Ziziphi iingenelo ze-tirzepatide?
3.Ziziphi iingenelo ze-retatrutide?
4.Ukuthelekisa iiNzuzo zeRetatrutide kunye neTirzepatide
Uthini umahluko phakathi kwe-tirzepatide kunye ne-retatrutide?
Umahluko omkhulu phakathi kwe-tirzepatide kunye ne-retatrutide kwisakhiwo sabo.I-Tirzepatide indibaniselwano yamacandelo amathathu asebenzayo - i-liraglutide, i-glucagon-like peptide-1 agonist (GLP-1);i-analogue ye-oxyntomodulin;kunye ne-analogue ye-GLP-2.I-Retarutide, ngakolunye uhlangothi, iqulunqwe yinto enye esebenzayo - i-exenatide, enye i-GLP-1 igxininise kakhulu kwi-pancreas.Zombini iziyobisi zisetyenziselwa ukulawula uhlobo lwe-2 yeswekile ngokunyusa ukuveliswa kwe-insulin kunye nokunciphisa amanqanaba eglucose yegazi.Nangona kunjalo, i-retarutide ibonakaliswe ukunciphisa ukutya ngokufanelekileyo ngakumbi kune-tirzepatide yodwa ngenxa yempembelelo yayo kwiihomoni ezibandakanyeka kwindlala kunye nokuhlutha.Ngaloo ndlela, inokusetyenziswa njengenxalenye yendlela edibeneyo yokulawula ubunzima kubantu abanesifo seswekile abakhulu kakhulu okanye abagqithiseleyo.
Ziziphi iingenelo ze-tirzepatide?
①Ukulawulwa kwe-glycemic ephuculweyo kunye namanqanaba e-A1C, ekhokelela kwimpilo engcono
Tirzepatide, i-glucagon-like peptide 1 receptor agonist kunye ne-GLP-1 / glucose-exhomekeke kwi-insulinotropic polypeptide (GIP) i-agonist ephindwe kabini, yindlela entsha yokonyango yohlobo lwe-2 yeswekile.Kufunyenwe ukuba kusebenza ngakumbi kune-retatrutide ekuphuculeni ulawulo lwe-glycemic kunye namanqanaba e-A1C.Kwizilingo zeklinikhi, i-tirzepatide idibene nokunciphisa okukhulu kumanqanaba e-A1C kwiiveki ze-12 xa kuthelekiswa ne-retatrutide (-2.3% vs -1.8%), ekhokelela kwiziphumo ezingcono zezempilo kwizigulane.
②Ukunciphisa umngcipheko weziganeko ze-cardiovascular ezifana nesifo senhliziyo kunye ne-stroke
I-Tirzepatide ibonelela ngoluhlu lwezibonelelo ezinokubakho kubantu abasengozini yeziganeko zentliziyo ezifana nesifo sentliziyo kunye nesifo sohlangothi.Uphononongo luka-2019 olupapashwe kwijenali iLancet yafumanisa ukuba abantu abathatha i-tirzepatide banomngcipheko ophantsi kakhulu weziganeko ezimbi zentliziyo (MACE) xa kuthelekiswa nabo bathatha i-retatrutide.Oku kubandakanya i-35% yokunciphisa i-MACE xa kuthelekiswa ne-retatrutide, ebonisa ukuba akukho mmahluko omkhulu kwimpembelelo kwimingcipheko ye-cardiovascular.Ngethuba lokufunda, abaphandi baqaphela ukuba izigulane ezithatha i-tirzepatide zafumana amazinga aphantsi e-coronary artery disease, i-myocardial infarction, ukungaphumeleli kwentliziyo kunye ne-stroke kunezo zeqela le-retatrutide.Ukongezelela, abathathi-nxaxheba abathatha i-tirzepatide baphinde bachaza amanqanaba aphuculweyo okulawula iswekile yegazi kunye nokuzuza okuncinci kobunzima xa kuthelekiswa nalabo bathatha i-retatrutide.Okokugqibela, kubalulekile ukuqaphela ukuba abantu abathatha i-tirzepatide abakhuselwanga kuphela kwi-MACE kodwa baye bancipha kumanqanaba e-HbA1c (umakishi womonakalo wexesha elide weswekile) kunye nepesenti yamafutha omzimba xa kuthelekiswa namanqanaba asisiseko.Ekugqibeleni, ezi ziphumo zibonisa ukuba kunokwenzeka ukuba i-tirzepatide inciphise iziganeko ze-cardiovascular ezinxulumene nohlobo lwe-2 yeswekile kunye nokubonelela ngeenzuzo ezongezelelweyo ezinxulumene nokubunjwa komzimba.
Ubunzima bomzimba obusezantsi xa kuthelekiswa ne-retatrutide, enokunceda ukunciphisa umngcipheko wezifo ezinxulumene nokutyeba
I-Tirzepatide ineenzuzo ezininzi xa kuthelekiswa ne-retatrutide, ngakumbi xa kuziwa kubunzima bomzimba.Uphononongo lufumene ukuba i-tirzepatide inokukhokelela ekunciphiseni okubaluleke ngakumbi kubunzima bomzimba kune-retatrutide kwixesha elide.Oku kunokubalelwa kubuchule bayo bokuvuselela umsebenzi we-GLP-1 receptor kunye nokukhuthaza ukuhlutha.Ukongeza, i-tirzepatide ifunyenwe ukunciphisa amanqatha esisu ngcono kune-retatrutide, enokunceda ukunciphisa umngcipheko wesifo seswekile, izifo zentliziyo, kunye nezinye izifo ezinxulumene nokutyeba.Ngaphezu koko, i-tirzepatide ibonakaliswe ukunciphisa amanqanaba eswekile yegazi ngokufanelekileyo kune-retatrutide.Ezi ziphumo zidibeneyo zinokuphucula iziphumo zempilo ngokubanzi ezinxulumene nokutyeba kunye nokungasebenzi kakuhle kwe-metabolic.
③Ukonyuka kwamanqanaba amandla ngenxa yokuphucula i-glucose metabolism
Enye yeenzuzo eziphambili zokuthatha i-tirzepatide kukukwazi ukunyusa amanqanaba amandla ngenxa yokuphucula i-glucose metabolism.Oku kungenxa yokuba i-GLP1 receptor agonists ithanda umsebenzi we-tirzepatide ngokuvuselela ukukhutshwa kwe-insulin ekuphenduleni amanqanaba aphezulu eswekile yegazi.Ngokwandisa imveliso ye-insulin kunye nokuphucula i-glucose metabolism, umzimba unokusebenzisa i-glucose eninzi yepetroli kwaye oku kunokukhokelela ekunyuseni kwamandla.Ukongeza, i-GLP1 i-receptor agonists inokunciphisa ukutya, okukhokelela ekunciphiseni iminqweno yokutya kunye nokuphuculwa kolawulo lobunzima.
Ziziphi iingenelo ze-retatrutide?
I-Retatrutideliyeza elisebenza ixesha elide elitofwayo elisetyenziselwa ukunyanga isifo seswekile sesibini.Ivunyiwe yi-US Food and Drug Administration (FDA) ngale njongo.Izibonelelo ze-retatrutide zininzi, okwenza kube yinto ekhangayo phakathi kwamanye amayeza esifo seswekile.
Ukuqala, i-retatrutide isebenza ngokukhawuleza xa ifakwe kwaye iziphumo zayo zinokuvakala kwiiyure ezingama-24 zolawulo.Oku kuyenza isebenze ngokukhawuleza kunezinye iitofu ezithatha ixesha elide ezifana ne-tirzepatide, enokuthi ithathe ukuya kwiiveki ezininzi phambi kokuba naziphi na iziphumo ezibonakalayo zibonwe kumanqanaba eswekile yegazi.
Ukongezelela, uphando lubonise ukuba i-retatrutide iyasebenza ekunciphiseni amanqanaba e-A1C kubantu abanesifo sikashukela sohlobo lwe-2 xa kuthathwa kunye nokutya kunye nokutshintsha kokuzivocavoca.Ulingo lwezonyango luye lwabonisa ukuba i-retatrutide inceda ukunciphisa amanqanaba e-glucose yokuzila kunye nokulawulwa kwe-glycemic jikelele kubasebenzisi xa kuthelekiswa ne-placebo.Kwezinye iimeko, abantu abangakhange bafumane nzuzo kumayeza omlomo weswekile baye bafumana iziphumo eziyimpumelelo ngonyango lwe-retatrutide.
Ekugqibeleni, enye yeenzuzo ezinkulu ze-retatrutide yinkqubo yayo yokulawula elula;ifuna inaliti enye ngeveki endaweni yezitofu ezininzi zemihla ngemihla njengolunye unyango lweswekile.Oku kunokwenza ukukhathalela isifo seswekile kube lula kwaye kuncede ekuphuculeni ukuthotyelwa kwesigulane kwisicwangciso sonyango ekuhambeni kwexesha.
Ukuthelekisa iiNzuzo zeRetatrutide kunye neTirzepatide
Xa kuziwa ekusebenzeni, i-retatrutide ibonakaliswe ukunciphisa amanqanaba e-HbA1c nge-1.9-2.4%, xa kuthelekiswa ne-Tirzepatide eyanciphisa amanqanaba e-HbA1c nge-1.5-2%.Omabini amayeza aneziphumo ebezingalindelekanga ezifanayo, ezifana nesicaphucaphu kunye nentloko.Nangona kunjalo, abanye abantu banokufumanisa ukuba bafumana iziphumo ebezingalindelekanga ezimbalwa nge-Retatrutide kune-Tirzepatide ngenxa yeemfuno zayo zedosi esezantsi.
Ngokokhuseleko, i-retarutide ixhatshazwa kakuhle xa isetyenziswe kwiidosi ezicetyiswayo kwaye ayinyusi ingozi ye-hypoglycemia okanye ibangele ukufumana ubunzima njengamanye unyango lweswekile.Kwelinye icala, iTirzepatide inomngcipheko ophezulu wokujongwa kwendawo yokutofa ngenxa yobukhulu bayo.Ukongeza, ukuba kuthathwe iidosi ezingaphezulu kunokubangela i-hypoglycemia enzima kunye nokuzuza ubunzima.
Isishwankathelo, zombini i-retarutide kunye ne-tirzepatide zikhetho ezisebenzayo zokulawula uhlobo lwe-2 yeswekile kodwa enye inokufaneleka ngakumbi kwizigulana ezithile ngokuxhomekeke kwiimfuno zabo.I-Retarutide inika ukusebenza kakuhle kunye neziphumo ebezingalindelekanga ezimbalwa ngelixa ikwakhuseleka ngakumbi kwiidosi ezicetyiswayo;nangona kunjalo, i-Tirzepatide inokubonelela ngokunciphisa okukhulu kumanqanaba e-HbA1c kodwa inokuthwala umngcipheko ophezulu wemiphumo emibi kakhulu xa ingasetyenziswanga kakuhle.Ekugqibeleni, kubalulekile ukubonisana nogqirha wakho ukuze wenze isigqibo sokuba loluphi unyango olulungele wena ngokusekelwe kwiimeko zakho ezithile kunye neenjongo zempilo.
Qala unyango lwakho lwe-tirzepatide kunye ne-semaglutide e-LianFu
Ixesha lokuposa: Mar-18-2024